NDA 050635 · Abraxis Pharm
Clindamycin Phosphate In Dextrose 5%
Clindamycin Phosphate · Injection
Last checked: Nov 19, 2026Latest source record: Dec 22, 1989 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Dec 22, 1989
Approved uses
1
Original approval plus efficacy supplements
Registered trials
274
66 Phase 3, 28 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 22, 1989 Original approval · Type 3 - New Dosage Form
1 products under this application
- CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% · CLINDAMYCIN PHOSPHATE EQ 900MG BASE/100ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Clindamycin" as an intervention, any sponsor and status, largest first.
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
University of OxfordAcademic, hospital or other
NCT04093765 · 5,542 participants · Start Nov 1, 2018 · Primary completion Dec 31, 2019
Drug: Antimalarials · For: Plasmodium Falciparum Malaria
Sites: Mae Sot, Thailand
- Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial VaginosisPivotal-lookingCompleted
University Hospital, LilleAcademic, hospital or other
NCT00642980 · 3,105 participants · Start Apr 2006 · Primary completion Jun 2011
Drug: Clindamycin; Placebo and 1 more · For: Pregnancy
Sites: Lille, France
- Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00729937 · 2,265 participants · Start Apr 2009 · Primary completion May 2013
Drug: Cephalexin; Clindamycin and 1 more · For: Staphylococcal Infection
Sites: Phoenix, Arizona; Sylmar, California; Baltimore, Maryland · 5 sites in all
- Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated MalariaPivotal-lookingCompleted
Universiteit AntwerpenAcademic, hospital or other
NCT01374581 · 2,117 participants · Start May 2012 · Primary completion Jun 2014
Drug: Artemether/Lumefantrine; Artesunate/Amodiaquine and 1 more · For: Malaria
Sites: Kinshasa, Republic of the Congo; Kiruhura, Uganda
- Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean InfectionPivotal-lookingCompleted
Alan TitaAcademic, hospital or other
NCT01235546 · 2,013 participants · Start May 2011 · Primary completion Dec 2015
Drug: Azithromycin and standard of care; Placebo and standard of care · For: Endometritis; Wound Infection; Abscess and 1 more
Sites: Birmingham, Alabama; New Orleans, Louisiana; Jackson, Mississippi · 9 sites in all
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolPivotal-lookingCompleted
The Camelot FoundationAcademic, hospital or other
NCT04349410 · 1,800 participants · Start Apr 11, 2020 · Primary completion Sep 14, 2020
Drug: Hydroxychloroquine, Azithromycin; Hydroxychloroquine, Doxycycline and 9 more · For: CoVid 19 Positive
Sites: Los Angeles, California
- Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center TrialPivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT03283878 · 1,770 participants · Start Oct 24, 2017 · Primary completion Nov 20, 2024
Drug: Cefazolin · For: Arthropathy of Knee; Antibiotic Prophylaxis
Sites: San Francisco, California; Atlanta, Georgia; Towson, Maryland · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Prognostic factors for streptococcal toxic shock syndrome: systematic review and meta-analysis.
Bartoszko JJ, Elias Z, Rudziak P, et al. · BMJ Open 2022 · Meta-Analysis, Systematic Review
- Antibiotics for uncomplicated skin abscesses: systematic review and network meta-analysis.
Wang W, Chen W, Liu Y, et al. · BMJ Open 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Maternal colonization with group B Streptococcus and antibiotic resistance in China: systematic review and meta-analyses.
Wang J, Zhang Y, Lin M, et al. · Ann Clin Microbiol Antimicrob 2023 · Meta-Analysis, Systematic Review
- Antibiotic regimens for postpartum endometritis.
Mackeen AD, Packard RE, Ota E, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Prevalence of antibiotic-resistant Cutibacterium acnes (formerly Propionibacterium acnes) isolates, a systematic review and meta-analysis.
Beig M, Shirazi O, Ebrahimi E, et al. · J Glob Antimicrob Resist 2024 · Meta-Analysis, Systematic Review
- Topical preparations for the treatment of mild-to-moderate acne vulgaris: systematic review and network meta-analysis.
Stuart B, Maund E, Wilcox C, et al. · Br J Dermatol 2021 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Abraxis Pharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.